269. De-Labeling of Allergies to Beta-Lactam Antibiotics (De-LABeL) Program - Development and Pilot Of An Inpatient Pediatric Program
Session: Poster Abstract Session: Pediatric Antimicrobial and Diagnostic Stewardship
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • De-LABeL - Prospective Pilot Poster (with algorithm)_IDWeek_final for printing Sep28.pdf (1.1 MB)
  • Background: Self-reported β-lactam allergy (BLA) labels are common. The implementation of inpatient penicillin allergy testing in the adult setting has been shown to improve antimicrobial use. The impact of this intervention in the pediatric inpatient setting is unknown.

    Objectives: We sought to develop and pilot an inpatient β-lactam allergy delabeling program in a pediatric tertiary-care center.

    Methods: In collaboration with the Allergy and Immunology, Infectious Diseases and Pharmacy Divisions, a De-Labeling of Allergies to Beta-Lactams (De-LABeL) program has been developed for integration into routine patient care at the Hospital for Sick Children. The oral provocation challenge (OPC) was chosen as the delabeling intervention and the program has been piloted on the General Pediatric service.

    Results: An algorithm was created to assist clinicians in identifying appropriate candidates for an inpatient OPC. Reported reactions were risk-stratified using a systematic framework. A two-step OPC (10% followed by 90% of a weight-based treatment dose of the potential allergen) was used. Following the OPC, patient families received a letter to take to their primary care provider and pharmacist, to provide communication about the status of their BLA.

    During the 3-month pilot on the General Pediatric service, 32 children with a BLA label were assessed, and one third of patients (n=11, 34.4%) were delabeled. Four families declined the OPC. Nine patients (28.1%) were not eligible for an OPC based on the algorithm. The majority of the remaining patients (n=6, 18.7%) could not complete the OPC during their admission and were referred for outpatient allergy assessment. All assessments were completed in less than 48 hours from the time of admission. No adverse events were observed during the OPCs.

    Conclusion: Preliminary data from the De-LABeL program pilot is promising and the feedback from knowledge users has been positive. The next phase will be program implementation hospital-wide.

    Jacqueline Wong, MD, FRCPC, FAAP1, Kathryn Timberlake, PharmD2, Adelle Atkinson, MD, FRCPC3 and Michelle Science, MD, MSc, FRCPC1, (1)Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada, (2)Pharmacy, The Hospital for Sick Children, Toronto, ON, Canada, (3)Allergy & Immunology, The Hospital for Sick Children, Toronto, ON, Canada

    Disclosures:

    J. Wong, None

    K. Timberlake, None

    A. Atkinson, None

    M. Science, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.